All : 24 Posts

-, 2025, All May 6th, 2025 0 Comments

Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease

Antwerp, Belgium, May 6, 2025 Agomab Therapeutics NV (“Agomab”) today announced latebreaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastrointestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) developed for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). The interim results were presented by Florian Rieder,

Read more

2025, All April 10th, 2025 0 Comments

Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025

Antwerp, Belgium, April 10, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ-RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD), will be presented as a late-breaking presentation at Digestive

Read more

2024, All November 18th, 2024 0 Comments

Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors

Antwerp, Belgium, November 18, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience

Read more

2024, All October 25th, 2024 0 Comments

Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis- focused Pipeline

Antwerp, Belgium, October 25, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129,

Read more

-, 2024, All July 11th, 2024 0 Comments

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Antwerp, Belgium, July 11, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In

Read more

-, 2024, All June 6th, 2024 0 Comments

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Antwerp, Belgium, June 6, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AGMB-447, its inhaled, small molecule inhibitor of ALK5. Agomab is evaluating AGMB-447 as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) in a Phase 1 clinical trial (NCT06181370).

Read more

-, 2023, All December 14th, 2023 0 Comments

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

Ghent, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Read more

-, 2023, All November 29th, 2023 0 Comments

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Ghent, Belgium, November 29, 2023 – Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer. As

Read more